Confidence in metabolite identification dictates the applicability of metabolomics to regulatory toxicology

Julia M. Malinowska, Mark R. Viant*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)
291 Downloads (Pure)

Abstract

The strength of omics technologies in toxicology is their ability to identify pathways of toxicity. Although pathway discovery is not required for chemical risk assessment, it can generate molecular biomarkers that accelerate the use of molecular assays in regulatory toxicology. For metabolomics, this application is limited by the challenge of metabolite identification. Here, we construct a framework around the confidence in identification of metabolites and molecular pathways and map multiple toxicometabolomics studies to this framework. This reveals that few studies achieve the highest level of confidence defined by the Metabolomics Standards Initiative. However, we argue that the level of confidence required is dependent on the regulatory application. For some, such as chemical grouping, current practices can suffice, whereas other applications require a more rigorous approach to metabolite identification.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalCurrent Opinion in Toxicology
Volume16
Early online date17 Mar 2019
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • Biomarker discovery
  • Chemical risk assessment
  • Mass spectrometry
  • Metabolite annotation
  • Molecular key event
  • NMR spectroscopy

ASJC Scopus subject areas

  • Toxicology

Fingerprint

Dive into the research topics of 'Confidence in metabolite identification dictates the applicability of metabolomics to regulatory toxicology'. Together they form a unique fingerprint.

Cite this